CD274 and cancer: Several biomarkers, including tumor mutation burden (TMB), PD‐L1 expression, microsatellite instability and tumor neoantigen‐related mutation burden (TNB), could effectively predict the overall response of treatments with anti‐PD‐1 antibodies in certain cancers.22